Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 23, 2023 16:05 ET | Source: BioAtla, Inc.

BioAtla Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Progress

- Cleared dose-limiting toxicity (DLT) observation period with more frequent, dose-intensive regimen of CAB-AXL BA3011; anticipated leiomyosarcoma (LMS) cohort readout in 2H23 - Initiated the...
March 16, 2023 08:00 ET | Source: BioAtla, Inc.

BioAtla to Announce Fourth Quarter and Full-Year 2022 Financial Results and Provide Business Highlights

SAN DIEGO, March 16, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
February 27, 2023 08:07 ET | Source: BioAtla, Inc.

BioAtla Announces Change in Executive Leadership

SAN DIEGO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
February 23, 2023 08:00 ET | Source: BioAtla, Inc.

BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3182, a CAB-EpCAMxCAB-CD3 Bispecific T-Cell Engager for the Treatment of Advanced Adenocarcinoma

Following the IND clearance, the Company is advancing into a Phase 1 clinical study Potentially addressing most common subtypes of adenocarcinoma including colon, lung, breast, pancreas, and prostate...
January 10, 2023 08:00 ET | Source: BioAtla, Inc.

BioAtla Provides Clinical Program Updates and Upcoming 2023 Milestones

Mecbotamab vedotin (BA3011) Phase 2 part 1 interim results in PD-1 failure NSCLC continues to show strong antitumor activity in a highly refractory population with additional patients enrolled BA3011...
December 22, 2022 08:00 ET | Source: BioAtla, Inc.

BioAtla to Participate in the 41st Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Dec. 22, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
November 08, 2022 08:00 ET | Source: BioAtla, Inc.

BioAtla to Participate in the Jefferies London Healthcare Conference

SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
November 04, 2022 09:08 ET | Source: BioAtla, Inc.

BioAtla Announces $65 Million Underwritten Offering of its Common Stock

SAN DIEGO, Nov. 04, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
November 03, 2022 16:01 ET | Source: BioAtla, Inc.

BioAtla Reports Third Quarter 2022 Financial Results and Highlights Recent Progress

Mecbotamab vedotin (BA3011) Phase 2 part 1 interim results in NSCLC continue to show antitumor activity with additional patients enrolledBA3011 Undifferentiated Pleomorphic Sarcoma (UPS) enrollment in...
October 27, 2022 08:00 ET | Source: BioAtla, Inc.

BioAtla to Announce Third Quarter 2022 Financial Results and Provide Business Highlights on November 3, 2022

SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...